Arginine deprivation for ASS1-deficient mesothelioma.
Talha Khan
TK
Burki
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001124:Argininosuccinate Synthase / Q000172:deficiency*; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D006867:Hydrolases / Q000009:adverse effects / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D008654:Mesothelioma / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D000086002:Mesothelioma, Malignant; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011092:Polyethylene Glycols; D006867:Hydrolases; C512527:ADI PEG20; D001124:Argininosuccinate Synthase